A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs
Athletic Greens International
Summary
This study is a triple-blind, placebo-controlled, randomized controlled trial of 120 adults that will evaluate the impact of a novel nutritional supplement on improving nutrient gaps and changing nutrient status and the gut microbiome among glucagon-like peptide-1 receptor agonist (GLP-1 RA) users.
Eligibility
- Age range
- 18–59 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Be male or female * Be aged 18-59. * Has a BMI between 20-31.9. * Anyone currently taking GLP-1 medication at their maintenance dose (week 8+), and without any plans to alter their dosage. This includes: Semaglutide (Ozempic®, Wegovy®, Rybelsus®), Liraglutide (Saxenda®, Victoza®), Dulaglutide (Trulicity®), Exenatide (Byetta®, Bydureon®), Lixisenatide (Adlyxin®) * Anyone willing to follow the study protocol, including immediately prior to the all blood tests, duplicating their diet for 72 hours (3 days), refraining from caffeine and exercise for 24 hours, and fasting for…
Interventions
- Dietary SupplementAG1 - Nutritional Supplement
AG1 - Nutritional Supplement
- Dietary SupplementPlacebo
Maltodextrin Placebo
Location
- CitruslabsSanta Monica, California